Dose-dependent effects of propranolol on extinction learning and return of fear

Phase 1

• Conditions: Experimental study with healthy participants recruited from the general population; no vulnerable individuals or clinical groups will be involved. Our objective is to test whether propranolol administration has a dose-dependent effect on the facilitation of extinction learning and subsequent return of fear.; Therapeutic area: Psychiatry and Psychology [F] - Psychological processes [F02]

• Registration Number: EUCTR2018-003409-25-BE
• Lead Sponsor: KU Leuven

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-10-02
• Last Update Posted: 29 November 2021

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 144

Inclusion Criteria

Healthy participants 18-40 years old.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 144
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

We will exclude pregnant women, people with cardiovascular conditions, lung problems, neurologic conditions (e.g., epilepsy, seizures, convulsions), serious psychiatric conditions (depression, mania, psychosis, anxiety disorder) in the past or the present, or other serious medical conditions, people with pace-makers or other electronic implants, people with (uncorrected) hearing impairments, people with pain, injury or other medical conditions at the hands or wrists, and people who have been advised by their physician to keep away from stressful situations.
Specific exclusion criteria also apply for the administration of propranolol. Those include a history of low blood pressure, dizziness, or
fainting, inability to perform moderate exercise, cardiac problems in first-degree relative, a history of diabetes, liver or kidney problems,
metabolic acidosis, excessive production of thyroid hormone, circulatory problems, current use of medication that acts on the cardiac system,
antihypertensive drugs, migraine medication, blood sugar level depression medication, gastric acid blinding drugs, anti-inflammatory agents, antidepressants, antipsychotics, anxiolytics, asthma medication, drugs against dizziness, migraine, tuberculosis, or psoriasis, known allergy for propranolol, current systolic blood pressure below 90 or diastolic blood pressure below 60, current heart rate at rest below 60. We will also exclude all participants with a score of 26 or above on the Anxiety Sensitivity Index (questionnaire).

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified